Targeting Mutant Fibroblast Growth Factor Receptors in Cancer

由 Greulich, Heidi, Pollock, Pamela M.
出版 2011

Lineage specific biomarkers predict response to FGFR inhibition

由 Loch, David C., Pollock, Pamela M.
發表在 Cancer Discov (2012)

Fibroblast Growth Factor Receptor 2 Isoforms Detected via Novel RNA ISH as Predictive Biomarkers for Progestin Therapy in Atypical Hyperplasia and Low-Grade Endometrial Cancer

由 Sengal, Asmerom T., Smith, Deborah, Rogers, Rebecca, Snell, Cameron E., Williams, Elizabeth D., Pollock, Pamela M.
發表在 Cancers (Basel) (2021)

Common variation in the fibroblast growth factor receptor 2 gene is not associated with endometriosis risk

由 Zhao, Zhen Zhen, Pollock, Pamela M., Thomas, Shane, Treloar, Susan A., Nyholt, Dale R., Montgomery, Grant W.
出版 2008

Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation

由 Karlsson, Thomas, Krakstad, Camilla, Tangen, Ingvild Løberg, Hoivik, Erling A., Pollock, Pamela M., Salvesen, Helga B., Lewis, Aurélia E.
發表在 Oncotarget (2016)

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wildtype PTEN status

由 Byron, Sara A, Loch, David C, Wellens, Candice L, Wortmann, Andreas, Wu, Jiayi, Wang, John, Nomoto, Kenichi, Pollock, Pamela M
出版 2012

Cellular Settings Mediating Src Substrate Switching between Focal Adhesion Kinase Tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) Tyrosine 734

由 Wortmann, Andreas, He, Yaowu, Christensen, Melinda E., Linn, MayLa, Lumley, John W., Pollock, Pamela M., Waterhouse, Nigel J., Hooper, John D.
出版 2011

FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features

由 Byron, Sara A., Gartside, Michael, Powell, Matthew A., Wellens, Candice L., Gao, Feng, Mutch, David G., Goodfellow, Paul J., Pollock, Pamela M.
出版 2012

Correction: FGFR2 Point Mutations in 466 Endometrioid Endometrial Tumors: Relationship with MSI, KRAS, PIK3CA, CTNNB1 Mutations and Clinicopathological Features

由 Byron, Sara A., Gartside, Michael, Powell, Matthew A., Wellens, Candice L., Gao, Feng, Mutch, David G., Goodfellow, Paul J., Pollock, Pamela M.
出版 2012

The ‘melanoma-enriched’ microRNA miR-4731-5p acts as a tumour suppressor

由 Stark, Mitchell S., Tom, Lisa N., Boyle, Glen M., Bonazzi, Vanessa F., Soyer, H. Peter, Herington, Adrian C., Pollock, Pamela M., Hayward, Nicholas K.
發表在 Oncotarget (2016)

Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of zoledronic acid in vivo

由 Landgraf, Marietta, Lahr, Christoph A., Sanchez-Herrero, Alvaro, Meinert, Christoph, Shokoohmand, Ali, Pollock, Pamela M., Hutmacher, Dietmar W., Shafiee, Abbas, McGovern, Jacqui A.
發表在 Bone Res (2019)

Correction: Humanized bone facilitates prostate cancer metastasis and recapitulates therapeutic effects of Zoledronic acid in vivo

由 Landgraf, Marietta, Lahr, Christoph A., Sanchez-Herrero, Alvaro, Meinert, Christoph, Shokoohmand, Ali, Pollock, Pamela M., Hutmacher, Dietmar W., Shafiee, Abbas, McGovern, Jacqui A.
發表在 Bone Res (2020)

A crystallographic snapshot of tyrosine trans-phosphorylation in action

由 Chen, Huaibin, Xu, Chong-Feng, Ma, Jinghong, Eliseenkova, Anna V., Li, Wanqing, Pollock, Pamela M., Pitteloud, Nelly, Miller, W. Todd, Neubert, Thomas A., Mohammadi, Moosa
出版 2008

The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

由 Byron, Sara A, Chen, Huaibin, Wortmann, Andreas, Loch, David, Gartside, Michael G, Dehkhoda, Farhad, Blais, Steven P, Neubert, Thomas A, Mohammadi, Moosa, Pollock, Pamela M
出版 2013

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer

由 Packer, Leisl M., Stehbens, Samantha J., Bonazzi, Vanessa F., Gunter, Jennifer H., Ju, Robert J., Ward, Micheal, Gartside, Michael G., Byron, Sara A., Pollock, Pamela M.
發表在 Mol Oncol (2019)

Aspirin reduces the incidence of metastasis in a pre-clinical study of Braf mutant serrated colorectal neoplasia

由 Kane, Alexandra M., Liu, Cheng, Fennell, Lochlan J., McKeone, Diane M., Bond, Catherine E., Pollock, Pamela M., Young, Graeme, Leggett, Barbara A., Whitehall, Vicki L. J.
發表在 Br J Cancer (2021)

Identifying Therapies to Combat Epithelial Mesenchymal Plasticity-Associated Chemoresistance to Conventional Breast Cancer Therapies Using An shRNA Library Screen

由 Bhatia, Sugandha, Blick, Tony, Pinto, Cletus, Waltham, Mark, Monkman, James, Ivanova, Ekaterina, Pollock, Pamela M., Nagaraj, Shivashankar H., Wiegmans, Adrian P., Haviv, Izhak, Simpson, Kaylene J., Thompson, Erik W.
發表在 Cancers (Basel) (2020)

miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma

由 Stark, Mitchell S., Bonazzi, Vanessa F., Boyle, Glen M., Palmer, Jane M., Symmons, Judith, Lanagan, Catherine M., Schmidt, Christopher W., Herington, Adrian C., Ballotti, Robert, Pollock, Pamela M., Hayward, Nicholas K.
發表在 Oncotarget (2015)

Homodimerization Controls the Fibroblast Growth Factor 9 Subfamily's Receptor Binding and Heparan Sulfate-Dependent Diffusion in the Extracellular Matrix

由 Kalinina, Juliya, Byron, Sara A., Makarenkova, Helen P., Olsen, Shaun K., Eliseenkova, Anna V., Larochelle, William J., Dhanabal, Mohanraj, Blais, Steven, Ornitz, David M., Day, Loren A., Neubert, Thomas A., Pollock, Pamela M., Mohammadi, Moosa
出版 2009

A Phase II Trial of Brivanib in Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

由 Powell, Matthew A., Sill, Michael W., Goodfellow, Paul J., Benbrook, Doris M., Lankes, Heather A., Leslie, Kimberly K., Jeske, Yvette, Mannel, Robert S., Spillman, Monique A, Lee, Paula S., Hoffman, James S., McMeekin, D. Scott, Pollock, Pamela M.
發表在 Gynecol Oncol (2014)